This study reports the results of a long-term economic evaluation of riluzole in the treatment
of amyotrophic lateral sclerosis (ALS) versus best supportive care in the United Kingdom …

This study reports the results of a long-term cost-effectiveness analysis of riluzole in the
treatment of amyotrophic lateral sclerosis (ALS) in the United Kingdom. The aim was to …

This study reports the results of a long-term economic evaluation of riluzole in the treatment
of amyotrophic lateral sclerosis (ALS) versus best supportive care in the United Kingdom …

Objective: In patients with amyotrophic lateral sclerosis, long term treatment with riluzole has
been reported to improve survival or tracheostomy-free survival in comparison with placebo …

We conducted a cost-benefit analysis of riluzole therapy in patients with amyotrophic lateral
sclerosis (ALS; motor neuron disease; Lou Gehrig's disease). The survival of patients with …

Amyotrophic lateral sclerosis (ALS) is a difficult to diagnose, fatal, progressive degenerative
disease with an average survival time of 2 to 5 years. Percutaneous endoscopic gastrotomy …

The paper in this issue by Ginsberg and Lowe [1] reviews the cost effectiveness of
treatments for amyotrophic lateral sclerosis (ALS), a progressive degenerative disorder with …

Objectives Reexamine cost-effectiveness of riluzole in the treatment of amyotrophic lateral
sclerosis (ALS) in light of recent advances in disease staging and understanding of stage …

Background Amyotrophic lateral sclerosis (ALS) is a devastating disease which leads to loss
of muscle function and paralysis. Historically, clinical drug development has been …

In health care, choices are constantly being made about alternative uses of scarce
resources, and health economics offers a framework for analysing these choices and for …